These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 30607817)

  • 1. Neratinib in Early-Stage Breast Cancer: A Profile of Its Use in the EU.
    Dhillon S
    Clin Drug Investig; 2019 Feb; 39(2):221-229. PubMed ID: 30607817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
    Martin M; Holmes FA; Ejlertsen B; Delaloge S; Moy B; Iwata H; von Minckwitz G; Chia SKL; Mansi J; Barrios CH; Gnant M; Tomašević Z; Denduluri N; Šeparović R; Gokmen E; Bashford A; Ruiz Borrego M; Kim SB; Jakobsen EH; Ciceniene A; Inoue K; Overkamp F; Heijns JB; Armstrong AC; Link JS; Joy AA; Bryce R; Wong A; Moran S; Yao B; Xu F; Auerbach A; Buyse M; Chan A;
    Lancet Oncol; 2017 Dec; 18(12):1688-1700. PubMed ID: 29146401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Chan A; Delaloge S; Holmes FA; Moy B; Iwata H; Harvey VJ; Robert NJ; Silovski T; Gokmen E; von Minckwitz G; Ejlertsen B; Chia SKL; Mansi J; Barrios CH; Gnant M; Buyse M; Gore I; Smith J; Harker G; Masuda N; Petrakova K; Zotano AG; Iannotti N; Rodriguez G; Tassone P; Wong A; Bryce R; Ye Y; Yao B; Martin M;
    Lancet Oncol; 2016 Mar; 17(3):367-377. PubMed ID: 26874901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. U.S. Food and Drug Administration Approval: Neratinib for the Extended Adjuvant Treatment of Early-Stage HER2-Positive Breast Cancer.
    Singh H; Walker AJ; Amiri-Kordestani L; Cheng J; Tang S; Balcazar P; Barnett-Ringgold K; Palmby TR; Cao X; Zheng N; Liu Q; Yu J; Pierce WF; Daniels SR; Sridhara R; Ibrahim A; Kluetz PG; Blumenthal GM; Beaver JA; Pazdur R
    Clin Cancer Res; 2018 Aug; 24(15):3486-3491. PubMed ID: 29523624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial.
    Chan A; Moy B; Mansi J; Ejlertsen B; Holmes FA; Chia S; Iwata H; Gnant M; Loibl S; Barrios CH; Somali I; Smichkoska S; Martinez N; Alonso MG; Link JS; Mayer IA; Cold S; Murillo SM; Senecal F; Inoue K; Ruiz-Borrego M; Hui R; Denduluri N; Patt D; Rugo HS; Johnston SRD; Bryce R; Zhang B; Xu F; Wong A; Martin M;
    Clin Breast Cancer; 2021 Feb; 21(1):80-91.e7. PubMed ID: 33183970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neratinib after trastuzumab-based adjuvant therapy in patients from Asia with early stage HER2-positive breast cancer.
    Iwata H; Masuda N; Kim SB; Inoue K; Rai Y; Fujita T; Chiu J; Ohtani S; Takahashi M; Miyaki T; Lu YS; Xu B; Yap YS; Bustam A; Yao B; Zhang B; Bryce R; Chan A
    Future Oncol; 2019 Jul; 15(21):2489-2501. PubMed ID: 31140297
    [No Abstract]   [Full Text] [Related]  

  • 7. Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial.
    Delaloge S; Cella D; Ye Y; Buyse M; Chan A; Barrios CH; Holmes FA; Mansi J; Iwata H; Ejlertsen B; Moy B; Chia SKL; Gnant M; Smichkoska S; Ciceniene A; Martinez N; Filipović S; Ben-Baruch NE; Joy AA; Langkjer ST; Senecal F; de Boer RH; Moran S; Yao B; Bryce R; Auerbach A; Fallowfield L; Martin M
    Ann Oncol; 2019 Apr; 30(4):567-574. PubMed ID: 30689703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial.
    Chia SKL; Martin M; Holmes FA; Ejlertsen B; Delaloge S; Moy B; Iwata H; von Minckwitz G; Mansi J; Barrios CH; Gnant M; Tomašević Z; Denduluri N; Šeparović R; Kim SB; Jakobsen EH; Harvey V; Robert N; Smith J; Harker G; Zhang B; Eli LD; Ye Y; Lalani AS; Buyse M; Chan A
    Breast Cancer Res; 2019 Mar; 21(1):39. PubMed ID: 30867034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial.
    Holmes FA; Moy B; Delaloge S; Chia SKL; Ejlertsen B; Mansi J; Iwata H; Gnant M; Buyse M; Barrios CH; Silovski T; Šeparović R; Bashford A; Zotano AG; Denduluri N; Patt D; Gokmen E; Gore I; Smith JW; Loibl S; Masuda N; Tomašević Z; Petráková K; DiPrimeo D; Wong A; Martin M; Chan A;
    Eur J Cancer; 2023 May; 184():48-59. PubMed ID: 36898233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neratinib as extended adjuvant therapy in patients with copositive early breast cancer: German health technology assessment-driven analyses from the ExteNET study.
    Lüftner D; Tesch H; Schmidt M; Hartkopf AD; Streicher S; Resch A; Genovese L; Rosé C; Valenti R; Harbeck N
    Eur J Cancer; 2021 Jun; 150():268-277. PubMed ID: 33971386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations.
    Kourie HR; Chaix M; Gombos A; Aftimos P; Awada A
    Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):947-57. PubMed ID: 27284682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast Cancer.
    Schwartz NRM; Flanagan MR; Babigumira JB; Steuten LM; Roth JA
    J Manag Care Spec Pharm; 2019 Oct; 25(10):1133-1139. PubMed ID: 31556818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neratinib in Combination With Trastuzumab for the Treatment of Patients With Advanced HER2-positive Breast Cancer: A Phase I/II Study.
    Blackwell KL; Zaman K; Qin S; Tkaczuk KHR; Campone M; Hunt D; Bryce R; Goldstein LJ;
    Clin Breast Cancer; 2019 Apr; 19(2):97-104.e4. PubMed ID: 30655172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patterns of occurrence and implications of neratinib-associated diarrhea in patients with HER2-positive breast cancer: analyses from the randomized phase III ExteNET trial.
    Mortimer J; Di Palma J; Schmid K; Ye Y; Jahanzeb M
    Breast Cancer Res; 2019 Feb; 21(1):32. PubMed ID: 30813966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neratinib in the early-stage/extended adjuvant breast cancer patient.
    O'Shaughnessy JA; Isaacs C; O'Regan R
    Clin Adv Hematol Oncol; 2020 Aug; 18 Suppl 12(8):1-20. PubMed ID: 33843843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neratinib, A Novel HER2-Targeted Tyrosine Kinase Inhibitor.
    Tiwari SR; Mishra P; Abraham J
    Clin Breast Cancer; 2016 Oct; 16(5):344-348. PubMed ID: 27405796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial.
    Barcenas CH; Hurvitz SA; Di Palma JA; Bose R; Chien AJ; Iannotti N; Marx G; Brufsky A; Litvak A; Ibrahim E; Alvarez RH; Ruiz-Borrego M; Chan N; Manalo Y; Kellum A; Trudeau M; Thirlwell M; Garcia Saenz J; Hunt D; Bryce R; McCulloch L; Rugo HS; Tripathy D; Chan A;
    Ann Oncol; 2020 Sep; 31(9):1223-1230. PubMed ID: 32464281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant neratinib promotes ferroptosis and inhibits brain metastasis in a novel syngeneic model of spontaneous HER2
    Nagpal A; Redvers RP; Ling X; Ayton S; Fuentes M; Tavancheh E; Diala I; Lalani A; Loi S; David S; Anderson RL; Smith Y; Merino D; Denoyer D; Pouliot N
    Breast Cancer Res; 2019 Aug; 21(1):94. PubMed ID: 31409375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neratinib for the treatment of HER2-positive early stage breast cancer.
    Echavarria I; López-Tarruella S; Márquez-Rodas I; Jerez Y; Martin M
    Expert Rev Anticancer Ther; 2017 Aug; 17(8):669-679. PubMed ID: 28649882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neratinib for the treatment of early-stage, hormone receptor-positive, HER2-overexpressed breast cancer.
    Jerez Y; Herrero B; Arregui M; Morón B; Martín M; Echavarría I
    Future Oncol; 2020 Jun; 16(17):1165-1177. PubMed ID: 32458702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.